My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Substances
Ondansetron

Ondansetron

A-Z
Search for:
Ondansetron 2 AMPULES
Swiss Remedies
Substance Overview and History

Ondansetron, a 5-HT3 receptor antagonist, is widely recognized for its effectiveness in preventing nausea and vomiting in clinical settings. Beyond its established use, this drug has emerged as a key player in cardiovascular research, specifically for its impact on small-conductance Ca2+-activated K+ (SK) channels. At nanomolar concentrations, ondansetron inhibits these channels, influencing cardiac repolarization and potentially addressing arrhythmias linked to heightened SK activity. However, its potent blocking effect on SK currents also highlights its role in drug-induced long QT syndrome (diLQTS), where it may prolong cardiac repolarization. Ondansetron’s effects extend to both wild-type and variant SK channels, as demonstrated in studies on human and murine models. Genetic predispositions, including mutations in the KCNN2 gene, further illuminate its nuanced effects. This dual nature underscores its therapeutic potential while necessitating caution in cardiovascular applications.

References:

Ko, J.-S., Guo, S., Hassel, J., Celestino-Soper, P., Lynnes, T.C., Tisdale, J.E., Zheng, J.J., Taylor, S.E., Foroud, T., Murray, M.D., Kovacs, R.J., Li, X., Lin, S.-F., Chen, Z., Vatta, M., Chen, P.-S. and Rubart, M., 2018. Ondansetron and its effects on IKAS and long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is the primary use of ondansetron?
Ondansetron is primarily used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery by blocking 5-HT3 receptors in the gastrointestinal tract and central nervous system.
References:

Ko, J.-S., Guo, S., Hassel, J., Celestino-Soper, P., Lynnes, T.C., Tisdale, J.E., Zheng, J.J., Taylor, S.E., Foroud, T., Murray, M.D., Kovacs, R.J., Li, X., Lin, S.-F., Chen, Z., Vatta, M., Chen, P.-S. and Rubart, M., 2018. Ondansetron and its effects on IKAS and long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology.

How does ondansetron affect the heart?
Ondansetron inhibits small-conductance Ca2+-activated K+ (SK) currents, which play a role in cardiac repolarization. This action can help manage certain arrhythmias but also carries a risk of drug-induced long QT syndrome (diLQTS).
References:

Ko, J.-S., Guo, S., Hassel, J., Celestino-Soper, P., Lynnes, T.C., Tisdale, J.E., Zheng, J.J., Taylor, S.E., Foroud, T., Murray, M.D., Kovacs, R.J., Li, X., Lin, S.-F., Chen, Z., Vatta, M., Chen, P.-S. and Rubart, M., 2018. Ondansetron and its effects on IKAS and long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology.

What is drug-induced long QT syndrome (diLQTS)?
DiLQTS is a condition where certain medications prolong the QT interval on an ECG, increasing the risk of life-threatening arrhythmias. Ondansetron has been associated with this condition, particularly in genetically predisposed individuals.
References:

Ko, J.-S., Guo, S., Hassel, J., Celestino-Soper, P., Lynnes, T.C., Tisdale, J.E., Zheng, J.J., Taylor, S.E., Foroud, T., Murray, M.D., Kovacs, R.J., Li, X., Lin, S.-F., Chen, Z., Vatta, M., Chen, P.-S. and Rubart, M., 2018. Ondansetron and its effects on IKAS and long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology.